Cognition in the Study of Tamoxifen and Raloxifene

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to assess the effects of tamoxifen and raloxifene on cognitive aging in selected cognitively-healthy women.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Wake Forest University
• Collaborator: National Institute on Aging (NIA)
• Treatments: Estrogen Receptor Modulators; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen

Criteria

Inclusion Criteria:

• Women enrolled in STAR trial at a site participating in Co-STAR

• 65 years of age or older

• Have been randomized into STAR but have not started taking the study drug OR enrolled in STAR for a minimum of one year

• Have not been diagnosed with dementia

• Have signed a separate consent document for the Co-STAR Study

• Previous diagnoses of chronic neurologic disease (Parkinson's disease, stroke, epilepsy, multiple sclerosis), history of head injury, depression, alcohol addiction, drug addiction, and other neurologic or psychiatric conditions will be recorded but will not serve as exclusion factors for this study

Exclusion Criteria:

• Not enrolled in the STAR Trial

• Younger than 65 years of age

• Diagnosed with dementia